FindTrial
Sign In

Background PAH Therapy

DRUG4 trials

Sponsors

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA, Merck Sharp & Dohme LLC

Conditions

Pulmonary Arterial Hypertension

Phase 2

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)
CompletedNCT06664801
Merck Sharp & Dohme LLCPulmonary Arterial Hypertension
Start: 2024-11-14End: 2025-11-20Updated: 2025-12-05
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)
Active, not recruitingNCT06925750
Merck Sharp & Dohme LLCPulmonary Arterial Hypertension
Start: 2025-05-12End: 2028-06-16Target: 130Updated: 2025-12-05

Phase 3

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)
CompletedNCT04576988
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAPulmonary Arterial Hypertension
Start: 2021-01-25End: 2022-12-06Updated: 2024-09-19

Phase 4

A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)
Not yet recruitingNCT07600723
Merck Sharp & Dohme LLCPulmonary Arterial Hypertension
Start: 2026-11-04End: 2028-04-03Target: 30Updated: 2026-08-07

Related Papers

A systematic review and metanalysis of safety and efficacy parameters of sotatercept in the therapy of pulmonary arterial hypertension.
2026-06-05
Transforming PAH care in Italy: a clinical and economic evaluation of sotatercept add-on therapy.
2025-12-17
Long-Term Mortality and Morbidity Impact on Patients with Pulmonary Arterial Hypertension (PAH) If Access to Sotatercept Is Delayed: A Simulation Model
Advances in Therapy2025-06-17
Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies
European Respiratory Journal2025-01-3014 citations
Transforming PAH care in Italy: a clinical and economic evaluation of sotatercept add-on therapy
2025-01-01
Transforming PAH care in Italy: a clinical and economic evaluation of sotatercept add-on therapy
OPAL (Open@LaTrobe) (La Trobe University)2025-01-01
Efficacy and safety of sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension: A pooled analysis of PULSAR and STELLAR.
2024-12-057 citations
The Impact of Immunogenicity on the Pharmacokinetics, Efficacy, and Safety of Sotatercept in a Phase III Study of Pulmonary Arterial Hypertension
Clinical Pharmacology & Therapeutics2023-11-2812 citations
Abstract 13038: Predictive Value of Cardiac Function Parameters and NT-proBNP in Patients With Pulmonary Arterial Hypertension (PAH) Treated With Sotatercept in the STELLAR Trial
Circulation2023-11-07
Population Health Model Predicting the Long-Term Impact of Sotatercept on Morbidity and Mortality in Patients with Pulmonary Arterial Hypertension (PAH).
2023-10-1813 citations
Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension
New England Journal of Medicine2023-03-06546 citations
Abstract 10188: Sotatercept Phase 3 Program Design and Rationale: A Novel Treatment for Pulmonary Arterial Hypertension
Circulation2021-11-163 citations